Featured Publications
Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis
Sehrawat T, Arab J, Liu M, Amrollahi P, Wan M, Fan J, Nakao Y, Pose E, Navarro‐Corcuera A, Dasgupta D, Liao C, He L, Mauer A, Avitabile E, Ventura‐Cots M, Bataller R, Sanyal A, Chalasani N, Heimbach J, Watt K, Gores G, Gines P, Kamath P, Simonetto D, Hu T, Shah V, Malhi H. Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. Hepatology 2021, 73: 571-585. PMID: 32246544, PMCID: PMC7541595, DOI: 10.1002/hep.31256.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseAlcohol-associated cirrhosisAlcoholic hepatitisAH subjectsHealthy controlsHeavy drinkersLiver diseaseEtiology of ESLDEV concentrationEnd-stage liver disease (MELD) scoreExtracellular vesiclesRisk profilingPathogenesis of AHLiver Disease scoreCholestatic liver diseaseNonalcoholic steatohepatitisRisk stratificationClinical criteriaPrognostic performanceDisease scoreDiagnostic biomarkersDisease controlEV countsDiseaseDrinkersAn Open‐Label, Dose‐Escalation Study to Assess the Safety and Efficacy of IL‐22 Agonist F‐652 in Patients With Alcohol‐associated Hepatitis
Arab J, Sehrawat T, Simonetto D, Verma V, Feng D, Tang T, Dreyer K, Yan X, Daley W, Sanyal A, Chalasani N, Radaeva S, Yang L, Vargas H, Ibacache M, Gao B, Gores G, Malhi H, Kamath P, Shah V. An Open‐Label, Dose‐Escalation Study to Assess the Safety and Efficacy of IL‐22 Agonist F‐652 in Patients With Alcohol‐associated Hepatitis. Hepatology 2020, 72: 441-453. PMID: 31774566, PMCID: PMC7250715, DOI: 10.1002/hep.31046.Peer-Reviewed Original ResearchConceptsAlcohol-associated hepatitisSevere alcohol-associated hepatitisSerious adverse eventsMELD scoreDay 28Hepatic regenerationLille scoreAdverse eventsInterleukin-22Randomized placebo-controlled trialDose-escalating studyPlacebo-controlled trialDose-escalation studyMarkers of inflammationComparator cohortOpen labelFirst doseInflammatory markersSerum aminotransferasesSerum cytokinesEfficacy signalsSerum bilirubinMean agePatient cohortRegeneration markers
2021
Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery
Nakao Y, Amrollahi P, Parthasarathy G, Mauer A, Sehrawat T, Vanderboom P, Nair K, Nakao K, Allen A, Hu T, Malhi H. Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery. Nanomedicine Nanotechnology Biology And Medicine 2021, 36: 102430. PMID: 34174416, PMCID: PMC8418232, DOI: 10.1016/j.nano.2021.102430.Peer-Reviewed Original ResearchConceptsWeight loss surgeryHepatocyte-derived extracellular vesiclesPlasma levelsNAFLD resolutionExtracellular vesiclesWeight loss patientsLogistic regression analysisPlasma extracellular vesiclesNAFLD patientsLipid panelNASH patientsLoss patientsNAFLDInvasive biomarkersPatientsCare testGroup 22EV correlatesSteatosisSurgeryRegression analysisBiomarkersDifferential ultracentrifugationCorrelatesInflammation
2020
Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis
Bajaj JS, Reddy KR, O'Leary JG, Vargas HE, Lai JC, Kamath PS, Tandon P, Wong F, Subramanian RM, Thuluvath P, Fagan A, White MB, Gavis EA, Sehrawat T, de la Rosa Rodriguez R, Thacker LR, Sikaroodi M, Garcia-Tsao G, Gillevet PM. Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. Gastroenterology 2020, 159: 1715-1730.e12. PMID: 32687928, PMCID: PMC7680282, DOI: 10.1053/j.gastro.2020.07.019.Peer-Reviewed Original ResearchMeSH KeywordsAcute-On-Chronic Liver FailureAdultAgedBacteriaBiomarkersDatabases, FactualFecesFemaleGastrointestinal MicrobiomeHospital MortalityHumansLipidomicsLipidsLiver CirrhosisMaleMetabolomicsMiddle AgedNorth AmericaPatient AdmissionPredictive Value of TestsPrognosisProspective StudiesRisk AssessmentRisk FactorsTime FactorsConceptsDevelopment of ACLFSerum levelsClinical parametersStool samplesSerum metabolitesEnd-stage liver diseaseWhite blood cell countSerum samplesFecal microbiomeTertiary hepatology centersChronic liver failureDay of admissionMultiple centersTime of admissionBlood cell countNorth American ConsortiumLevels of phospholipidsMetabolomic analysisHepatology centersHospital admissionLiver failureClinical featuresLiver diseaseACLFEstrogen metabolites